JP2020505049A5 - - Google Patents

Download PDF

Info

Publication number
JP2020505049A5
JP2020505049A5 JP2019541188A JP2019541188A JP2020505049A5 JP 2020505049 A5 JP2020505049 A5 JP 2020505049A5 JP 2019541188 A JP2019541188 A JP 2019541188A JP 2019541188 A JP2019541188 A JP 2019541188A JP 2020505049 A5 JP2020505049 A5 JP 2020505049A5
Authority
JP
Japan
Prior art keywords
seq
recombinant adenovirus
cancer
site
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019541188A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020505049A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/016032 external-priority patent/WO2018140973A1/en
Publication of JP2020505049A publication Critical patent/JP2020505049A/ja
Publication of JP2020505049A5 publication Critical patent/JP2020505049A5/ja
Pending legal-status Critical Current

Links

JP2019541188A 2017-01-30 2018-01-30 複数トランスジーン組み換えアデノウイルス Pending JP2020505049A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762452342P 2017-01-30 2017-01-30
US62/452,342 2017-01-30
US201762520945P 2017-06-16 2017-06-16
US62/520,945 2017-06-16
PCT/US2018/016032 WO2018140973A1 (en) 2017-01-30 2018-01-30 Multiple transgene recombinant adenovirus

Publications (2)

Publication Number Publication Date
JP2020505049A JP2020505049A (ja) 2020-02-20
JP2020505049A5 true JP2020505049A5 (https=) 2021-03-11

Family

ID=62978741

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019541188A Pending JP2020505049A (ja) 2017-01-30 2018-01-30 複数トランスジーン組み換えアデノウイルス

Country Status (12)

Country Link
US (1) US20190352616A1 (https=)
EP (1) EP3574090A4 (https=)
JP (1) JP2020505049A (https=)
KR (1) KR20190128634A (https=)
CN (1) CN110741080A (https=)
AU (1) AU2018213417A1 (https=)
BR (1) BR112019015600A2 (https=)
CA (1) CA3052090A1 (https=)
IL (1) IL268291A (https=)
MX (1) MX2019008921A (https=)
SG (1) SG11201906973TA (https=)
WO (1) WO2018140973A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
KR102608590B1 (ko) 2014-09-24 2023-12-01 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양 살상 바이러스 및 이의 사용방법
WO2017147269A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
EP3532082A4 (en) 2016-12-12 2020-08-26 Salk Institute for Biological Studies SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES
EA201990822A1 (ru) 2017-04-12 2020-01-09 Эписентарикс, Инк. Иммуномодулирующие слитые белки
US20200155625A1 (en) * 2017-05-24 2020-05-21 Epicentrx, Inc. Anti-angiogenic adenovirus
CN112292449A (zh) 2018-04-09 2021-01-29 萨克生物研究学院 具有增强的复制特性的溶瘤腺病毒组合物
WO2022007800A1 (zh) * 2020-07-06 2022-01-13 嘉兴安宇生物科技有限公司 一种非洲猪瘟的重组腺病毒疫苗及其构建方法
EP4349975A4 (en) * 2021-05-25 2025-04-16 Voncolytic Therapeutics Co., Ltd. Chimeric broad-spectrum oncolytic adenovirus with multiple mechanisms synergizing with and enhancing efficacy of immunotherapy, and application thereof in tumor treatment
CN113249342B (zh) * 2021-05-25 2023-12-01 江苏万戎生物医药科技有限公司 一款多重机制协同和增效免疫治疗的嵌合型广谱溶瘤腺病毒及其在肿瘤治疗中的应用
WO2024015876A1 (en) 2022-07-13 2024-01-18 Epicentrx, Inc. Adenoviral vectors encapsulated in cationic liposomes, and preparation and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100896483B1 (ko) * 2007-07-13 2009-05-08 연세대학교 산학협력단 Il-12 및 4-1bbl을 발현하는 종양 선택적 살상 재조합아데노바이러스 및 수지상 세포를 유효성분으로 포함하는항종양용 약제학적 조성물
HUE026386T2 (en) * 2009-03-02 2016-06-28 Univ California Tumor-selective adenovirus e1a and e1b mutants
KR20130010121A (ko) * 2010-03-23 2013-01-25 인트렉손 코포레이션 치료적 단백질을 조건부로 발현하는 벡터,상기 벡터를 포함하는 숙주 세포 및 이의 용도
US20130243731A1 (en) * 2010-09-24 2013-09-19 Oncos Therapeutics Oy Oncolytic adenoviral vectors coding for monoclonal anti-ctla-4 antibodies
WO2013116778A2 (en) * 2012-02-02 2013-08-08 Board Of Regents Immunogenic adenovirus
DK2986311T3 (en) * 2013-04-18 2019-02-25 Tilt Biotherapeutics Oy IMPROVED ADOPTIVE CELL THERAPY
CN103614416B (zh) * 2013-09-30 2016-09-07 中国人民解放军第二军医大学东方肝胆外科医院 一种携带人穿膜肽p53与GM-CSF基因的重组溶瘤腺病毒及其用途
KR102608590B1 (ko) * 2014-09-24 2023-12-01 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양 살상 바이러스 및 이의 사용방법
US10232053B2 (en) * 2016-12-30 2019-03-19 Trieza Therapeutics, Inc. Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer

Similar Documents

Publication Publication Date Title
JP2020505049A5 (https=)
JP2020516293A5 (https=)
Ratajczak Igf2-H19, an imprinted tandem gene, is an important regulator of embryonic development, a guardian of proliferation of adult pluripotent stem cells, a regulator of longevity, and a ‘passkey’to cancerogenesis
Ding et al. Epithelial‐to‐mesenchymal transition of murine liver tumor cells promotes invasion
JP2020521470A5 (https=)
JP2022514420A5 (https=)
JP2019531728A5 (https=)
Xiao et al. Trefoil factors: Gastrointestinal-specific proteins associated with gastric cancer
JP2020516277A5 (https=)
CN108635380A (zh) 重组溶瘤病毒组合物及其在制备用于治疗肿瘤的药物中的应用
RU2016120618A (ru) Онколитический hsv-вектор
Yoon et al. CRISPR-Cas12a with an oAd induces precise and cancer-specific genomic reprogramming of EGFR and efficient tumor regression
EP1678193B1 (en) Hepatocellular carcinoma specific promoter and uses thereof
Hung et al. Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice
WO2014036807A1 (zh) 重组单纯疱疹病毒、其制备方法及应用
Ito et al. Genomic and transcriptional alterations of cholangiocarcinoma
Matrka et al. Dek overexpression in murine epithelia increases overt esophageal squamous cell carcinoma incidence
JP2025038139A5 (https=)
CN102796709A (zh) 肝癌特异性基因-病毒及其应用
RU2019132253A (ru) Новая днк-вакцина, нацеленная на pd-l1, для иммунотерапии рака
RU2011136280A (ru) HE-Ad5 АДЕНОВИРУСНЫЕ ВЕКТОРЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ
Riederer et al. Improving poxvirus-mediated antitumor immune responses by deleting viral cGAMP-specific nuclease
Hu et al. The anti-tumor efficacy of a recombinant oncolytic herpes simplex virus mediated CRISPR/Cas9 delivery targeting in HPV16-positive cervical cancer
JP2025500867A (ja) 前立腺癌ワクチン及びその使用
CN106318915A (zh) 重组单纯疱疹病毒HSV‑hTERTp_ICP4_LungCA‑GFP及诊断试剂盒